Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a fully integrated biotechnology company whose business model requires animal testing as a core component of its drug discovery and development process. The company states that after identifying a drug target, it is "often validated through further research in animal models." Its regulatory filings explicitly note that to market a drug product in the U.S., the company "need[s] to conduct both preclinical animal testing and human clinical trials." This includes juvenile animal studies in mice and monkeys as recommended by the FDA.

The company holds a U.S. License (No. 1760) issued by the USDA under the Animal Welfare Act and is listed in USDA inspection records. While Regeneron publishes a position statement committing to the principles of replacement, reduction, and refinement in animal research, its fundamental business of inventing and developing biologic medicines is currently dependent on animal testing to meet regulatory requirements for safety and efficacy.